TP53 and ovarian cancer: As summarized in Table 6, gene therapy formulations based on liposomes focus on the targeting of proto-oncogene cRAF with or without adjuvant chemotherapy (NCT00024661 and NCT00024648), delivery of tumor suppressor genes (FUS1, NCT00059605 and TP53, NCT02354547), or for the delivery of mRNA vaccines for treatment of ovarian cancer (NCT04163094) or melanoma (NCT02410733).